BRAF Mutation in Melanoma and Dietary Polyphenols as Adjunctive Treatment Strategy

Polyphenols in Human Health and Disease

Volumn 2, Issue , 2013, Pages 1353-1365

  Aquilato, Andrea ^a   Lopez, Victoria ^a   Doonan, Barbara ^a   Hsieh, Tze Chen ^a   Pinto, John Thomas ^a   Wu, Erxi ^a   Wu, Joseph M ^b  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b NORTH DAKOTA STATE UNIVERSITY   (United States)

Author keywords

BRAF V600E mutation; BRAF V600E mutation inhibitors; Dietary polyphenols; Melanoma; Resveratrol

Indexed keywords

EID: 84902570838     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-398456-2.00102-X     Document Type: Chapter

References (62)

1. Bosserhoff A. Melanoma Development 2011, Springer, New York.
2. Fedorenko I.V., Paraiso K.H., Smalley K.S. Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma. Biochem Pharmacol 2011, 82(3):201-209.
3. Society A.C. Cancer Facts & Figures 2012 2012, American Cancer Society, Atlanta.
4. Maldonado J.L., Fridlyand J., Patel H., Jain A.N., Busam K., Kageshita T., et al. Determinants of BRAF mutations in primary melanomas. J Natl Cancer Inst 2003, 95(24):1878-1890.
5. Marieb E.N., Hoehn K. Human Anatomy and Physiology 2010, Benjamin Cummings.
6. Nichols L., Sorahan T. Cancer incidence and cancer mortality in a cohort of UK semiconductor workers, 1970-2002. Occup Med (Lond) 2005, 55(8):625-630.
7. Clapp R.W. Mortality among US employees of a large computer manufacturing company: 1969-2001. Environ Health 2006, 5:30.
8. Sinks T., Steele G., Smith A.B., Watkins K., Shults R.A. Mortality among workers exposed to polychlorinated biphenyls. Am J Epidemiol 1992, 136(4):389-398.
9. Chen Y., Hall M., Graziano J.H., Slavkovich V., van Geen A., Parvez F., et al. A prospective study of blood selenium levels and the risk of arsenic-related premalignant skin lesions. Cancer Epidemiol Biomarkers Prev 2007, 16(2):207-213.
10. Kumar V., Robbins S.L. Robbins Basic Pathology 2007, Saunders/Elsevier.
11. Fitzpatrick T.B. The validity and practicality of sun-reactive skin types I through VI. Arch Dermatol 1988, 124(6):869-871.
12. Ross A.L., Sanchez M.I., Grichnik J.M. Nevogenesis: a benign metastatic process?. ISRN Dermatol 2011, 2011:813513.
13. Gaudi S., Messina J.L. Molecular bases of cutaneous and uveal melanomas. Patholog Res Int 2011, 2011:159421.
14. Li G., Satyamoorthy K., Herlyn M. N-cadherin-mediated intercellular interactions promote survival and migration of melanoma cells. Cancer Res 2001, 61(9):3819-3825.
15. Oancea E., Vriens J., Brauchi S., Jun J., Splawski I., Clapham D.E. TRPM1 forms ion channels associated with melanin content in melanocytes. Sci Signal 2009, 2(70):ra21.
16. Nayab N. Melanoma Growth & Overview of Stages. 2011 [accessed February 2012]. http://www.healthguideinfo.com/skin-cancer/p76527/.
17. Broekaert S.M., Roy R., Okamoto I., van den Oord J., Bauer J., Garbe C., et al. Genetic and morphologic features for melanoma classification. Pigment Cell Melanoma Res 2010, 23(6):763-770.
18. Types of Melanoma. 2011 [accessed February 2012]. http://www.melanoma.org/learn-more/melanoma-101/types-melanoma.
19. Cutaneous Melanoma. Medscape. [accessed February 2012]. http://www.emedicine.medscape.com.
20. Bollag G., Hirth P., Tsai J., Zhang J., Ibrahim P.N., Cho H., et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 2010, 467(7315):596-599.
21. Yajima I., Kumasaka M.Y., Thang N.D., Goto Y., Takeda K., Yamanoshita O., et al. RAS/RAF/MEK/ERK and PI3K/PTEN/AKT signaling in malignant melanoma progression and therapy. Dermatol Res Pract 2012, 2012:354191.
22. Smalley K.S. Understanding melanoma signaling networks as the basis for molecular targeted therapy. J Invest Dermatol 2010, 130(1):28-37.
23. Flaherty K.T., Puzanov I., Kim K.B., Ribas A., McArthur G.A., Sosman J.A., et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010, 363(9):809-819.
24. Katzung B.G. Basic & Clinical Pharmacology 2007, Lange Medical Books/McGraw-Hill, New York. 10th ed.
25. Garbe C., Eigentler T.K., Keilholz U., Hauschild A., Kirkwood J.M. Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist 2011, 16(1):5-24.
26. Niault T.S., Baccarini M. Targets of Raf in tumorigenesis. Carcinogenesis 2010, 31(7):1165-1174.
27. Heath E.M., Kaufman K.L., Christopherson R.I. B-RAF: A contributor to the melanoma phenotype. Int J Biochem Cell Biol 2011, 43(1):29-32.
28. Wellbrock C., Karasarides M., Marais R. The RAF proteins take centre stage. Nat Rev Mol Cell Biol 2004, 5(11):875-885.
29. Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S., et al. Mutations of the BRAF gene in human cancer. Nature 2002, 417(6892):949-954.
30. Zhang B.H., Guan K.L. Activation of B-Raf kinase requires phosphorylation of the conserved residues Thr598 and Ser601. EMBO J 2000, 19(20):5429-5439.
31. Pollock P.M., Harper U.L., Hansen K.S., Yudt L.M., Stark M., Robbins C.M., et al. High frequency of BRAF mutations in nevi. Nat Genet 2003, 33(1):19-20.
32. Yang H., Higgins B., Kolinsky K., Packman K., Go Z., Iyer R., et al. RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models. Cancer Res 2010, 70(13):5518-5527.
33. Buscà R., Abbe P., Mantoux F., Aberdam E., Peyssonnaux C., Eychène A., et al. Ras mediates the cAMP-dependent activation of extracellular signal-regulated kinases (ERKs) in melanocytes. EMBO J 2000, 19(12):2900-2910.
34. Roberts P.J., Der C.J. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 2007, 26(22):3291-3310.
35. Guan K.L., Figueroa C., Brtva T.R., Zhu T., Taylor J., Barber T.D., et al. Negative regulation of the serine/threonine kinase B-Raf by Akt. J Biol Chem 2000, 275(35):27354-27359.
36. Chang D.Z., Panageas K.S., Osman I., Polsky D., Busam K., Chapman P.B. Clinical significance of BRAF mutations in metastatic melanoma. J Transl Med 2004, 2(1):46.
37. Paraiso K.H., Fedorenko I.V., Cantini L.P., Munko A.C., Hall M., Sondak V.K., et al. Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy. Br J Cancer 2010, 102(12):1724-1730.
38. Shinozaki M., Fujimoto A., Morton D.L., Hoon D.S. Incidence of BRAF oncogene mutation and clinical relevance for primary cutaneous melanomas. Clin Cancer Res 2004, 10(5):1753-1757.
39. Bhatt K.V., Spofford L.S., Aram G., McMullen M., Pumiglia K., Aplin A.E. Adhesion control of cyclin D1 and p27Kip1 levels is deregulated in melanoma cells through BRAF-MEK-ERK signaling. Oncogene 2005, 24(21):3459-3471.
40. Wellbrock C., Marais R. Elevated expression of MITF counteracts B-RAF-stimulated melanocyte and melanoma cell proliferation. J Cell Biol 2005, 170(5):703-708.
41. Zheng B., Jeong J.H., Asara J.M., Yuan Y.Y., Granter S.R., Chin L., et al. Oncogenic B-RAF negatively regulates the tumor suppressor LKB1 to promote melanoma cell proliferation. Mol Cell 2009, 33(2):237-247.
42. Amiri K.I., Richmond A. Role of nuclear factor-kappa B in melanoma. Cancer Metastasis Rev 2005, 24(2):301-313.
43. Klein R.M., Aplin A.E. Rnd3 regulation of the actin cytoskeleton promotes melanoma migration and invasive outgrowth in three dimensions. Cancer Res 2009, 69(6):2224-2233.
44. Tuveson D.A., Weber B.L., Herlyn M. BRAF as a potential therapeutic target in melanoma and other malignancies. Cancer Cell 2003, 4(2):95-98.
45. King A.J., Patrick D.R., Batorsky R.S., Ho M.L., Do H.T., Zhang S.Y., et al. Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885. Cancer Res 2006, 66(23):11100-11105.
46. Tsai J., Lee J.T., Wang W., Zhang J., Cho H., Mamo S., et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci USA 2008, 105(8):3041-3046.
47. Bottos A., Martini M., Di Nicolantonio F., Comunanza V., Maione F., Minassi A.B., et al. Targeting oncogenic serine/threonine-protein kinase BRAF in cancer cells inhibits angiogenesis and abrogates hypoxia. Proc Natl Acad Sci USA 2012, 109(6):E353-359.
48. Joseph E.W., Pratilas C.A., Poulikakos P.I., Tadi M., Wang W., Taylor B.S., et al. The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. Proc Natl Acad Sci USA 2010, 107(33):14903-14908.
49. Smalley K.S., Lioni M., Dalla Palma M., Xiao M., Desai B., Egyhazi S., et al. Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas. Mol Cancer Ther 2008, 7(9):2876-2883.
50. Villanueva J., Vultur A., Lee J.T., Somasundaram R., Fukunaga-Kalabis M., Cipolla A.K., et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 2010, 18(6):683-695.
51. Aplin A.E., Kaplan F.M., Shao Y. Mechanisms of resistance to RAF inhibitors in melanoma. J Invest Dermatol 2011, 131(9):1817-1820.
52. Johannessen C.M., Boehm J.S., Kim S.Y., Thomas S.R., Wardwell L., Johnson L.A., et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 2010, 468(7326):968-972.
53. Nazarian R., Shi H., Wang Q., Kong X., Koya R.C., Lee H., et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 2010, 468(7326):973-977.
54. Shishodia S., Aggarwal B.B. Resveratrol: a polyphenol for all seasons. Resveratrol in Health and Disease 2006, 1-16. CRC Press, Boca Raton. B.B. Aggarwal, S. Shishodia (Eds.).
55. Bashayee A. Cancer prevention and treatment with resveratrol: from rodent studies to clinical trials. Cancer Prev Res (Phila) 2009, 2(2):409-418.
56. Niles R.M., McFarland M., Weimer M.B., Redkar A., Fu Y.M., Meadows G.G. Resveratrol is a potent inducer of apoptosis in human melanoma cells. Cancer Lett 2003, 190(2):157-163.
57. Shi H., Kong X., Ribas A., Lo R.S. Combinatorial treatments that overcome PDGFRβ-driven resistance of melanoma cells to V600EB-RAF inhibition. Cancer Res 2011, 71(15):5067-5074.
58. Søndergaard J.N., Nazarian R., Wang Q., Guo D., Hsueh T., Mok S., et al. Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032. J Transl Med 2010, 8:39.
59. Hsieh T.C., Wang Z., Hamby C.V., Wu J.M. Inhibition of melanoma cell proliferation by resveratrol is correlated with upregulation of quinone reductase 2 and p53. Biochem Biophys Res Commun 2005, 334(1):223-230.
60. Singh T., Katiyar S.K. Green tea catechins reduce invasive potential of human melanoma cells by targeting COX-2, PGE2 receptors and epithelial-to-mesenchymal transition. PLoS One 2011, 6(10):e25224.
61. vβ3 interaction. Cell Signal 2011, 23(10):1563-1577.
62. Bush J.A., Cheung K.J., Li G. Curcumin induces apoptosis in human melanoma cells through a Fas receptor/caspase-8 pathway independent of p53. Exp Cell Res 2001, 271:305-314.